High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Illerhaus G, Ferreri AJM, Wendler J, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, Röth A, Egerer G, Ernst T, Weber T, Hertenstein B, Lenz G, Dreyling M, Möhle R, Kobbe G, Schmidt CA, Brunnberg U, Panse J, Kneba M, Heinicke T, Schroll S, Larsen TS, Thurner L, Pukrop T, Salwender H, Naumann R, Hess G, Kroschinsky FP, Blystad AK, Keller U, Pulczynski EJ, Pedersen MB, Re F, Orsucci L, Pospiech L, La Rosée P, Deckert M, Ponzoni M, Gmehlin D, Backenstrass M, Jensch A, Valk E, Calimeri T, Kasenda B, Trepel M, Fricker H, Semenova I, Scherer F, von Gottberg P, Burger E, Grishina O, Hader C, Ihorst G, Finke J, Zucca E, Schorb E

Open source

DOI: 10.1016/s0140-6736(26)00917-7
Published: 2026 Aug 8
Container: Lancet (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00917-7,
  title = {High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.},
  author = {Illerhaus G and Ferreri AJM and Wendler J and Binder M and Borchmann P and Hasenkamp J and Stilgenbauer S and Röth A and Egerer G and Ernst T and Weber T and Hertenstein B and Lenz G and Dreyling M and Möhle R and Kobbe G and Schmidt CA and Brunnberg U and Panse J and Kneba M and Heinicke T and Schroll S and Larsen TS and Thurner L and Pukrop T and Salwender H and Naumann R and Hess G and Kroschinsky FP and Blystad AK and Keller U and Pulczynski EJ and Pedersen MB and Re F and Orsucci L and Pospiech L and La Rosée P and Deckert M and Ponzoni M and Gmehlin D and Backenstrass M and Jensch A and Valk E and Calimeri T and Kasenda B and Trepel M and Fricker H and Semenova I and Scherer F and von Gottberg P and Burger E and Grishina O and Hader C and Ihorst G and Finke J and Zucca E and Schorb E},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00917-7},
  url = {https://doi.org/10.1016/s0140-6736(26)00917-7}
}

RIS

TY  - JOUR
TI  - High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
AU  - Illerhaus G
AU  - Ferreri AJM
AU  - Wendler J
AU  - Binder M
AU  - Borchmann P
AU  - Hasenkamp J
AU  - Stilgenbauer S
AU  - Röth A
AU  - Egerer G
AU  - Ernst T
AU  - Weber T
AU  - Hertenstein B
AU  - Lenz G
AU  - Dreyling M
AU  - Möhle R
AU  - Kobbe G
AU  - Schmidt CA
AU  - Brunnberg U
AU  - Panse J
AU  - Kneba M
AU  - Heinicke T
AU  - Schroll S
AU  - Larsen TS
AU  - Thurner L
AU  - Pukrop T
AU  - Salwender H
AU  - Naumann R
AU  - Hess G
AU  - Kroschinsky FP
AU  - Blystad AK
AU  - Keller U
AU  - Pulczynski EJ
AU  - Pedersen MB
AU  - Re F
AU  - Orsucci L
AU  - Pospiech L
AU  - La Rosée P
AU  - Deckert M
AU  - Ponzoni M
AU  - Gmehlin D
AU  - Backenstrass M
AU  - Jensch A
AU  - Valk E
AU  - Calimeri T
AU  - Kasenda B
AU  - Trepel M
AU  - Fricker H
AU  - Semenova I
AU  - Scherer F
AU  - von Gottberg P
AU  - Burger E
AU  - Grishina O
AU  - Hader C
AU  - Ihorst G
AU  - Finke J
AU  - Zucca E
AU  - Schorb E
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00917-7
UR  - https://doi.org/10.1016/s0140-6736(26)00917-7
ER  -

APA

G, I., AJM, F., J, W., M, B., P, B., J, H., S, S., A, R., G, E., T, E., T, W., B, H., G, L., M, D., R, M., G, K., CA, S., U, B., J, P., M, K., T, H., S, S., TS, L., L, T., T, P., H, S., R, N., G, H., FP, K., AK, B., U, K., EJ, P., MB, P., F, R., L, O., L, P., P, L. R., M, D., M, P., D, G., M, B., A, J., E, V., T, C., B, K., M, T., H, F., I, S., F, S., P, V. G., E, B., O, G., C, H., G, I., J, F., E, Z., & E, S. (2026). High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00917-7

Source records

pubmed · retrieved 2026-09-25T16:28:54.515Z
europe-pmc · retrieved 2026-09-25T16:28:54.531Z